Catherine Bollard

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Catherine Bollard sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials 2 currently recruiting 7 completed early-phase tilt top decile by trial count

Catherine Bollard: 14 sponsored US clinical trials, 2 recruiting.

Catherine Bollard sponsors 14 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Refractory Viral Infections, with 1 trials.

Top-decile sponsor footprint

Catherine Bollard ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

14 total, page 1 of 1

RECRUITING Phase 1

Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

NCT03594981
RECRUITING Phase 1

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

NCT02203903
ACTIVE NOT RECRUITING Phase 2

HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

NCT04975698
ACTIVE NOT RECRUITING Phase 1

Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)

NCT04236479
ACTIVE NOT RECRUITING Phase 1

Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

NCT04248192
ACTIVE NOT RECRUITING Phase 1

Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

NCT03843294
ACTIVE NOT RECRUITING Phase 1

Multi-antigen T Cell Infusion Against Neuro-oncologic Disease

NCT03652545
COMPLETED Phase 1

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

NCT03485963
COMPLETED Phase 1

Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease

NCT02150551
COMPLETED Phase 1

Haploidentical Hematopoietic Stem Cell Transplantation

NCT02165007
COMPLETED Phase 1

Allogeneic Virus-specific T Cell Lines (VSTs)

NCT02510417
COMPLETED Phase 1

Multivirus-specific Cytotoxic T Lymphocytes (mCTL)

NCT02510404
COMPLETED Phase 1

Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)

NCT01945814
COMPLETED Phase 1

Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma

NCT01956084

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 1

Therapeutic Areas

Refractory Viral Infections 1
HIV Associated Lymphoma 1
HIV-Infected Individuals 1
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS 1
Congenital Heart Disease (CHD) 1
Viral Infection 1
Hodgkin Lymphoma 1
Brain Tumor 1
HIV Infections 1
Diffuse Large B Cell Lymphoma 1

What is open in the Catherine Bollard pipeline

2 recruiting of 14 indexed (14% open); 7 completed (50%).

Phase mix: 0 late (III/IV) vs 14 early (I/II) (early-phase heavy).

Top condition: Refractory Viral Infections (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Catherine Bollard: open-pipeline peers nationwide

Peers matched on 14 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Catherine Bollard sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%5%10%15%20% Total trials Recruiting share Catherine Bollard3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Catherine Bollard sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Catherine Bollard sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Catherine Bollard page

14 registered trials is a research-attention snapshot, not an endorsement of Catherine Bollard or any single study.

  • 2 of Catherine Bollard's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Refractory Viral Infections is the condition Catherine Bollard studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Refractory Viral Infections trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Catherine Bollard pipeline card: 14 registered trials from official public datasets.Report a data error.